产品
编 号：F174991
分子式：C39H48N4O4
分子量：636.82
分子式：C39H48N4O4
分子量：636.82
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 149402-51-7
产品详情
生物活性：
HPPH (Photochlor) is a second generation photosensitizer, which acts as a photodynamic therapy (PDT) agent.
体内研究：
Tumors are treated with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen can leads to enhancement of anti-tumor immunity, while retaining effective control of primary tumor growth. To test this hypothesis, a combination treatment regimen is devised in which Colo26-HA tumor-bearing BALB/c mice are treated with a HPPH-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg HPPH followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm2). Following illumination, mice are rested for 9 days; on the ninth day, mice are injected with HPPH. On day 10 following the first treatment, tumors are treated with a tumor control treatment regimen (illumination with 665 nm light for a total dose of 132 J/cm2 given).
体外研究：
Fluorescence image of 4T1 cells incubated with 0.49 μg/mL GO-PEG, 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 μM HPPH and 0.49 μg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 μM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact, the fluorescence of HPPH is rather weak.
HPPH (Photochlor) is a second generation photosensitizer, which acts as a photodynamic therapy (PDT) agent.
体内研究：
Tumors are treated with an immune-enhancing PDT regimen followed by a tumor-controlling PDT regimen can leads to enhancement of anti-tumor immunity, while retaining effective control of primary tumor growth. To test this hypothesis, a combination treatment regimen is devised in which Colo26-HA tumor-bearing BALB/c mice are treated with a HPPH-PDT regimen known to lead to enhanced anti-tumor immunity (0.4 μmoles/kg HPPH followed 18 h later by illumination with 665 nm light for a total dose of 48 J/cm2). Following illumination, mice are rested for 9 days; on the ninth day, mice are injected with HPPH. On day 10 following the first treatment, tumors are treated with a tumor control treatment regimen (illumination with 665 nm light for a total dose of 132 J/cm2 given).
体外研究：
Fluorescence image of 4T1 cells incubated with 0.49 μg/mL GO-PEG, 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 μM HPPH and 0.49 μg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 μM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact, the fluorescence of HPPH is rather weak.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备